Achieve Life Sciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Shares outstanding: 110,034,457 shares of common stock, $0.001 par value, were outstanding as of November 10, 2026.
- Sole product candidate: Cytisinicline is described as the company's sole product candidate, according to the filing.
- NDA status: The filing references an anticipated NDA resubmission following a Complete Response Letter, or CRL, received from the FDA.
- Sopharma arbitration: The filing discloses ongoing arbitration with Sopharma AD and notes its potential impact on NDA resubmission and commercialization plans.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
- Exchange listing: Common stock trades on NASDAQ:QUIT.
Achieve Life Sciences Discloses Cytisinicline Pipeline Status and Key Risks in September 2026 Quarterly Filing
Achieve Life Sciences, Inc. (NASDAQ:QUIT), a Delaware-incorporated biopharmaceutical company headquartered in Bothell, Washington, with offices in Vancouver, British Columbia, submitted its Form 10-Q for the quarterly period ended September 30, 2026. As of November 10, 2026, the company reported 110,034,457 shares of common stock outstanding at a par value of $0.001 per share.
According to the filing, cytisinicline remains the company's sole product candidate. The company disclosed that it anticipates resubmitting its New Drug Application following a Complete Response Letter from the FDA, and noted that the timing, costs, and outcome of arbitration proceedings with Sopharma AD could affect that resubmission and the company's commercialization plans. The filing does not specify a resolution date for either the FDA process or the arbitration.
The filing identifies several risk factors the company considers significant. These include the need to obtain additional financing to fund development, regulatory approval, and commercialization efforts, as well as existing debt obligations the company described as potentially impairing "flexibility and access to capital." The company also flagged potential adverse impacts from macroeconomic and geopolitical conditions, including "fluctuating inflation, interest and tariff rates" and "instability in the global banking system." Forward-looking statements in the filing are the company's own and are expressly subject to its cautionary language disclosing that actual results could differ materially from expectations.
What Was Disclosed
Achieve Life Sciences filed a 10-Q covering the quarter ended September 30, 2026, disclosing 110,034,457 shares outstanding, the status of its cytisinicline NDA resubmission following an FDA CRL, ongoing arbitration with Sopharma AD, and key financing and debt risks.




Please wait processing your request...